Doctors Archive - Cancer Treatment | Theranostics Australia

The OPS-201 trial has now commenced in Perth. This IPSEN sponsored trial involves the use of Lutetium-177 OPS-201 for treatment of progressive metastatic neuroendocrine tumours (NETs). Theranostics Australia is one of several sites worldwide currently recruiting (together with Peter Mac in Melbourne, Royal Free in London and Memorial Sloan Kettering in New York). For more information, please visit lnkd.in/gtXzzjh ... See MoreSee Less

View on Facebook

Theranostics Australia

4 weeks ago

Theranostics Australia (TA) and Perth Radiological Clinic (PRC) are offering a fellowship position in molecular imaging and therapy, to enable a qualified nuclear medicine physician or dual-trained radiologist/nuclear medicine specialist the opportunity to develop knowledge and expertise in these areas. Information about the position can be found at www.theranostics.com.au/careers ... See MoreSee Less

View on Facebook

Theranostics Australia

2 months ago

ARTICLE OF THE WEEK: The Journal of Nuclear Medicine (JNM) recently published an article on 177Lu-PSMA Radioligand Therapy (RLT) and its safety and effectiveness in reducing PSA and tumour burden in patients with metastatic castration-resistant prostate cancer (mCRPC). Read More >> ow.ly/OqDm30dWFZA ... See MoreSee Less

177Lu-PSMA radioligand therapy for prostate cancer

jnm.snmjournals.org

177Lu-PSMA radioligand therapy (RLT) using inhibitors of the prostate-specific membrane antigen (PSMA) is a novel therapeutic option in patients...

View on Facebook

Theranostics Australia

2 months ago

ARTICLE OF THE WEEK: The Journal of Nuclear Medicine (JNM) recently published an article on Gallium-68 PSMA PET/CT scanning and how it has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. Read More >> ow.ly/4eiq30dWFwl ... See MoreSee Less

The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study

jnm.snmjournals.org

68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This...

View on Facebook

Theranostics Australia

2 months ago

Theranostics Australia offers the latest approaches to treating Prostate Cancer*. Lutetium-177 PSMA therapy “…targets the disease in its advanced stages, offering new hope to patients who are running out of time.” – 10 News. For more information, please visit theranostics.com.au ... See MoreSee Less

An Australian development in prostate cancer treatment is being described as a game changer that could save 1000s of men. #TenNews

Ten News

Video

View on Facebook

View on Facebook

Archives